Fabry Disease

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2023-04-07
Clinical Trial Update: To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease [Phase 4]
A Phase 4 trial comparing switching from Agalsidase Alfa to Agalsidase Beta in male patients with classic Fabry disease has been withdrawn.
CLINICAL_TRIALS withdrawal · 2018-01-08
Clinical Trial Update: Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease [Phase 3]
Phase 3 study evaluating PRX-102 for gastrointestinal symptoms in Fabry disease has been withdrawn.
CLINICAL_TRIALS withdrawal · 2014-02-05
Clinical Trial Update: A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. [Phase 4]
A Phase 4 study evaluating treatment for Fabry disease in patients on chronic hemodialysis has been withdrawn.